Drug Addiction - Pipeline Review, H1 2017
ReportsWeb.com has announced the addition of the “Drug Addiction - Pipeline Review, H1 2017” this report provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.
(EMAILWIRE.COM, May 27, 2017 ) Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 6, 2, 28, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 12 and 5 molecules, respectively.
Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis
For more information about this report at http://www.reportsweb.com/drug-addiction-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689449/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Addex Therapeutics Ltd
Aelis Farma SAS
Aphios Corp
Astraea Therapeutics LLC
BioCorRx Inc
Cerecor Inc
Chiesi Farmaceutici SpA
Curemark LLC
Embera NeuroTherapeutics Inc
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals LLC
Heptares Therapeutics Ltd
Immunovaccine Inc
Indivior Plc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Kyorin Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
MedRev Pharma
NLS Pharma Group
Omeros Corp
Opiant Pharmaceuticals Inc
Orexigen Therapeutics Inc
P2D Bioscience
Saniona AB
Savant HWP Inc
Stada Arzneimittel AG
Teva Pharmaceutical Industries Ltd
Zynerba Pharmaceuticals Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689449/discount
List of Tables
Number of Products under Development for Drug Addiction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Drug Addiction - Pipeline by Addex Therapeutics Ltd, H1 2017
Drug Addiction - Pipeline by Aelis Farma SAS, H1 2017
Drug Addiction - Pipeline by Aphios Corp, H1 2017
Drug Addiction - Pipeline by Astraea Therapeutics LLC, H1 2017
Drug Addiction - Pipeline by BioCorRx Inc, H1 2017
Drug Addiction - Pipeline by Cerecor Inc, H1 2017
Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H1 2017
Drug Addiction - Pipeline by Curemark LLC, H1 2017
Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H1 2017
Drug Addiction - Pipeline by Immunovaccine Inc, H1 2017
Drug Addiction - Pipeline by Indivior Plc, H1 2017
Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H1 2017
Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H1 2017
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Drug Addiction - Pipeline by MedRev Pharma, H1 2017
Drug Addiction - Pipeline by NLS Pharma Group, H1 2017
Drug Addiction - Pipeline by Omeros Corp, H1 2017
Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H1 2017
Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2017
Drug Addiction - Pipeline by P2D Bioscience, H1 2017
Drug Addiction - Pipeline by Saniona AB, H1 2017
Drug Addiction - Pipeline by Savant HWP Inc, H1 2017
Drug Addiction - Pipeline by Stada Arzneimittel AG, H1 2017
Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
Drug Addiction - Dormant Projects, H1 2017
Drug Addiction - Dormant Projects, H1 2017 (Contd...1), H1 2017
Drug Addiction - Dormant Projects, H1 2017 (Contd...2), H1 2017
Drug Addiction - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689449/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 6, 2, 28, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 12 and 5 molecules, respectively.
Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis
For more information about this report at http://www.reportsweb.com/drug-addiction-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001689449/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Addex Therapeutics Ltd
Aelis Farma SAS
Aphios Corp
Astraea Therapeutics LLC
BioCorRx Inc
Cerecor Inc
Chiesi Farmaceutici SpA
Curemark LLC
Embera NeuroTherapeutics Inc
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals LLC
Heptares Therapeutics Ltd
Immunovaccine Inc
Indivior Plc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Kyorin Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
MedRev Pharma
NLS Pharma Group
Omeros Corp
Opiant Pharmaceuticals Inc
Orexigen Therapeutics Inc
P2D Bioscience
Saniona AB
Savant HWP Inc
Stada Arzneimittel AG
Teva Pharmaceutical Industries Ltd
Zynerba Pharmaceuticals Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001689449/discount
List of Tables
Number of Products under Development for Drug Addiction, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Drug Addiction - Pipeline by Addex Therapeutics Ltd, H1 2017
Drug Addiction - Pipeline by Aelis Farma SAS, H1 2017
Drug Addiction - Pipeline by Aphios Corp, H1 2017
Drug Addiction - Pipeline by Astraea Therapeutics LLC, H1 2017
Drug Addiction - Pipeline by BioCorRx Inc, H1 2017
Drug Addiction - Pipeline by Cerecor Inc, H1 2017
Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H1 2017
Drug Addiction - Pipeline by Curemark LLC, H1 2017
Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H1 2017
Drug Addiction - Pipeline by Immunovaccine Inc, H1 2017
Drug Addiction - Pipeline by Indivior Plc, H1 2017
Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H1 2017
Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H1 2017
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Drug Addiction - Pipeline by MedRev Pharma, H1 2017
Drug Addiction - Pipeline by NLS Pharma Group, H1 2017
Drug Addiction - Pipeline by Omeros Corp, H1 2017
Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H1 2017
Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H1 2017
Drug Addiction - Pipeline by P2D Bioscience, H1 2017
Drug Addiction - Pipeline by Saniona AB, H1 2017
Drug Addiction - Pipeline by Savant HWP Inc, H1 2017
Drug Addiction - Pipeline by Stada Arzneimittel AG, H1 2017
Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
Drug Addiction - Dormant Projects, H1 2017
Drug Addiction - Dormant Projects, H1 2017 (Contd...1), H1 2017
Drug Addiction - Dormant Projects, H1 2017 (Contd...2), H1 2017
Drug Addiction - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689449/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results